Citations

Clear

585 citation(s) found for "Tran, Ha".

De novo coding variants in the AGO1 gene cause a neurodevelopmental disorder with intellectual disability
Schalk, Audrey , Cousin, Margot A. , Dsouza, Nikita R., Challman, Thomas D. , Wain, Karen E. , Powis, Zöe , Minks, Kelly Q., Trimouille, Aurélien , Lasseaux, Eulalie , Michaud, Vincent , Van‐Gils, Julien , Spataro, Nino , Gabau, Elizabeth, Stolerman, Elliot , Washington, Camerun , Louie, Ray, Lanpher, Brendan C. , Kemppainen, Jennifer L., Innes, Micheil, Kooy, R. Frank , Goldenberg, Alice, Lecoquierre, François , Vera, Gabriella , Sheidley, Beth Rosen , Achkar, Christelle Moufawad El , Park, Meredith, Hamdan, Fadi F. , Michaud, Jacques L. , Lewis, Ann J., Zweier, Christiane , Wagner, Matias , Weigand, Heike, Journel, Hubert, Keren, Boris , Passemard, Sandrine , Mignot, Cyril , Brilstra, Eva H. , Itzikowitz, Gina, O’Heir, Emily , Allen, Jake, Donald, Kirsten A. , Korf, Bruce R. , Skelton, Tammi, Rudy, Natasha L. , Dobyns, William B. , Foss, Kimberly , Bosanko, Katherine A. , Alembik, Yves, Durand, Benjamin , Mau‐Them, Frédéric Tran , Ranza, Emmanuelle , Blanc, Xavier , Torti, Erin , Millan, Francisca , Dameron, Amy, Tokita, Mari, Zimmermann, Michael T. , Klee, Eric W. , Piton, Amélie , Gérard, Bénédicte , Ruiz, Anna , Stolerman, Elliot , Kooy, Frank , Lecoquierre, Francois , Reis, André , Wagner, Matias , Passemard, Sandrine , Tran Mau-Them, Frederic , Klee, Eric W , Piton, Amelie , Zimmermann, Michael T , Lacombe, Didier , Angelini, Chloé , Louie, Raymond J. , Meuwissen, Marije E. C. , Goldenberg, Alice , Diderich, Karin E. M. , Reis, André , Gassen, Koen L.I. van , Thompson, Michelle L. , Robin, Nathaniel H. , Zárate, Yuri A. , Antonarakis, Stylianos E. , McWalter, Kirsty

Mayo Clinic

Journal of Medical Genetics | December 20, 2021 | Volume: 59 | Issue: 10 | Pages: 965-975

10.1136/jmedgenet-2021-107751 | PMID 34930816 Get It

Background High-impact pathogenic variants in more than a thousand genes are involved in Mendelian forms of neurodevelopmental disorders (NDD). Methods This study describes the molecular and clinical characterisation of 28 probands with NDD harbouring heterozygous AGO1 coding variants, occurring de novo for all those whose transmission could have been verified (26/28). Results A total of 15 unique variants leading to amino acid changes or deletions were identified: 12 missense variants, two in-frame deletions of one codon, and one canonical splice variant leading to a deletion of two amino acid residues. Recurrently identified variants were present in several unrelated individuals: p.(Phe180del), p.(Leu190Pro), p.(Leu190Arg), p.(Gly199Ser), p.(Val254Ile) and p.(Glu376del). AGO1 encodes the Argonaute 1 protein, which functions in gene-silencing pathways mediated by small non-coding RNAs. Three-dimensional protein structure predictions suggest that these variants might alter the flexibility of the AGO1 linker domains, which likely would impair its function in mRNA processing. Affected individuals present with intellectual disability of varying severity, as well as speech and motor delay, autistic behaviour and additional behavioural manifestations. Conclusion Our study establishes that de novo coding variants in AGO1 are involved in a novel monogenic form of NDD, highly similar to the recently reported AGO2 -related NDD.
Polyurethane Foam Incorporated with Nanosized Copper-Based Metal-Organic Framework: Its Antibacterial Properties and Biocompatibility
Gwon, Kihak , Nam, Yunhee, Lee, Su Jung , Ngoc, Tran Minh , Yoo, Hyojong , Gwon, Kihak , Yoo, Hyojong , Lee, Do Nam

Mayo Clinic

International Journal of Molecular Sciences | December 19, 2021 | Volume: 22 | Issue: 24 | Pages: 13622

10.3390/ijms222413622 | PMID 34948419 Get It

Polyurethane foams (PUFs) have attracted attention as biomaterials because of their low adhesion to the wound area and suitability as biodegradable or bioactive materials. The composition of the building blocks for PUFs can be controlled with additives, which provide excellent anti-drug resistance and biocompatibility. Herein, nanosized Cu-BTC (copper(II)-benzene-1,3,5-tricarboxylate) was incorporated into a PUF via the crosslinking reaction of castor oil and chitosan with toluene-2,4-diisocyanate, to enhance therapeutic efficiency through the modification of the surface of PUF. The physical and thermal properties of the nanosized Cu-BTC-incorporated PUF (PUF@Cu-BTC), e.g., swelling ratio, phase transition, thermal gravity loss, and cell morphology, were compared with those of the control PUF. The bactericidal activities of PUF@Cu-BTC and control PUF were evaluated against Pseudomonas aeruginosa, Klebsiella pneumoniae, and methicillin-resistant Staphylococcus aureus. PUF@Cu-BTC exhibited selective and significant antibacterial activity toward the tested bacteria and lower cytotoxicity for mouse embryonic fibroblasts compared with the control PUF at a dose of 2 mg mL−1. The Cu(II) ions release test showed that PUF@Cu-BTC was stable in phosphate buffered saline (PBS) for 24 h. The selective bactericidal activity and low cytotoxicity of PUF@Cu-BTC ensure it is a candidate for therapeutic applications for the drug delivery, treatment of skin disease, and wound healing.
557: 4-DAY STANDARDIZED FTTE TRAINING IN ANESTHESIOLOGY: A MULTICENTER PROSPECTIVE STUDY OF RETENTION
Bughrara, Nibras , Tse, Whitney , Hamlin, Mark, Nikravan, Sara , Gold, Andrew, Pustavoitau, Aliaksei , Tran, Tim , Srour, Habib , Panzer, Oliver, Ata, Ashar , Díaz‐Gómez, José L. , Renew, J. Ross , Singh, Sumit Randhir , Deshpande, Ranjit

Mayo Clinic

Critical Care Medicine | December 16, 2021 | Volume: 50 | Issue: 1 | Pages: 270-270

10.1097/01.ccm.0000808552.74793.37 Get It

Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography–Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer
Martin, Ting , Savjani, Ricky R. , Pollom, Erqi L., Karnes, R. Jeffrey , Wong, J.K. , Motterle, Giovanni , Tosoian, Jeffrey J. , Klein, Eric A. , Stish, Bradley J. , Dess, Robert T. , Spratt, Daniel E. , Pilar, Avinash , Levin-Epstein, Rebecca , Wedde, Trude B. , Lilleby, Wolfgang , Fiano, Ryan , Stock, Richard G. , Demanes, D. Jeffrey, Huland, Hartwig , Martin, Santiago, Krauss, Daniel , Abu‐Isa, Eyad, Schwen, Zeyad , Pisansky, Thomas M. , Choo, C. Richard, Greco, Stephen , Deville, Curtiland , McNutt, Todd , DeWeese, Theodore L. , Ross, Ashley E. , Ciezki, Jay P. , Nickols, Nicholas G. , Bhat, Prashant , Shabsovich, David , Juarez, Jesus E. , Chong, Natalie, Kupelian, Patrick A. , Reiter, Robert E. , Steinberg, Michael L. , Elashoff, David , Horwitz, Eric M. , Tendulkar, Rahul D. , Czernin, Johannes, Gafita, Andrei , Romero, Tahmineh , Calais, Jérémie , Kishan, Amar U. , Davis, Brian J. , Deville, Curtiland , Spratt, Daniel E , Dess, Robert T , Klein, Eric A , Ma, Ting Martin , Calais, Jeremie , Xiang, Michael H. , Grogan, Tristan , Trock, Bruce J , Reddy, Chandana A. , Merrick, Gregory Stephen , Moran, Brian Joseph , Tran, Phuoc T , Martínez‐Monge, Rafael , Alam, Ridwan , Song, Daniel Y. , Boutros, Paul C. , Rettig, Matthew B. , Zaorsky, Nicholas G. , Berlin, Alejandro , Tward, Jonathan D. , Tilki, Derya

Mayo Clinic

JAMA Network Open | December 13, 2021 | Volume: 4 | Issue: 12 | Pages: e2138550

10.1001/jamanetworkopen.2021.38550 | PMID 34902034 Get It

402.3: Long-term Preservation of Isolated Human, Mouse, Porcine Islets and Human Stem Cell Derived Beta Cells (HUES-8 Cell Lines) Using a High Throughput Vitrification-Rewarming Modified Cryomesh Technique to Successfully Cure Diabetes in a Mouse With Tran
Tobolt, Diane, Sethia, Nikhil , Slama, Michael , Peterson, Quinn, Dutcher, Cari S. , Finger, Erik B. , Dutcher, Cari S , Rao, Joseph Sushil , Zhan, Li , Han, Zonghu , Bischof, John C , Finger, Erik B.

Mayo Clinic

Transplantation | November 28, 2021 | Volume: 105 | Issue: 12S1 | Pages: S27-S28

10.1097/01.tp.0000804440.47171.27 Get It

Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study
Comenzo, Raymond L. , Wechalekar, Ashutosh , Gibbs, Simon , Venner, Chris , Schönland, Stefan , Suzuki, Kenshi , Cibeira, María Teresa , Beksaç, Meral , Libby, Edward N., Valent, Jason , Wong, Sandy W. , Rosenzweig, Michael , Bumma, Naresh , Tran, NamPhuong, Qin, Xiang , Khaled, Samer K. , Vermeulen, Jessica, Merlini, Giampaolo , Merlini, Giampaolo , Schönland, Stefan , Beksac, Meral , Palladini, Giovanni , Kastritis, Efstathios , Minnema, Monique C , Wechalekar, Ashutosh D. , Jaccard, Arnaud , Dispenzieri, Angela , Lee, Hans C. , Sanchorawala, Vaishali , Mollee, Peter , Lu, Jin Ping , Gatt, Moshe E. , Kım, Kihyun , Valent, Jason Neil , Hungria, Vânia

Mayo Clinic

Blood | November 23, 2021 | Volume: 138 | Issue: Supplement 1 | Pages: 159-159

10.1182/blood-2021-146820 Get It

Abstract Introduction: Light chain (AL) amyloidosis is a plasma cell disease characterized by the deposition of insoluble amyloid fibrils into organs leading to organ dysfunction and death. The analysis at 6 and 12 months of the ANDROMEDA study (NCT03201965) showed that the addition of subcutaneous (SC) daratumumab to the standard of care combination of bortezomib, cyclophosphamide, and dexamethasone (VCd) was superior to VCd alone, with higher rates of hematologic complete response (CR) and an acceptable safety profile. Based on these findings daratumumab with VCd (D-VCd) was approved for newly diagnosed AL amyloidosis in January 2021 in the US and June 2021 in the EU. Here, we present data from the analysis at 18 months of the ANDROMEDA study. Methods: ANDROMEDA is a randomized, open-label, active-controlled phase 3 study including patients with newly diagnosed AL amyloidosis with measurable hematologic disease, ≥1 involved organ, cardiac stage I-IIIA, estimated glomerular filtration rate ≥20 mL/min, and absence of symptomatic multiple myeloma. Patients were randomized (1:1) to D-VCd or VCd for 6 28-day cycles. Bortezomib (1.3 mg/m 2), cyclophosphamide (300 mg/m 2 up to 500 mg per week), and dexamethasone (20-40 mg) were administered weekly. SC daratumumab (1800 mg co-formulated with recombinant human hyaluronidase PH20 in 15 mL) was administered once weekly in cycles 1 and 2 and every 2 weeks in cycles 3 to 6. Patients in the D-VCd arm received only SC daratumumab after cycle 6, every 4 weeks (up to a total of 24 cycles from first dose). The primary endpoint was overall (ie, at any time) hematologic CR rate, defined here as normalization of free light chain (FLC) levels and ratio (FLCr) and negative serum and urine immunofixation, confirmed at a subsequent visit; normalization of uninvolved FLC level and FLCr were not required if involved FLC was lower than the upper limit of normal. Secondary endpoints included major organ deterioration progression-free survival (PFS), organ response rate, time to hematologic response, overall survival (OS), and safety. Results: A total of 388 patients were randomized to receive D-VCd (N=195) or VCd alone (N=193). At the May 2021 clinical cutoff, the median duration of treatment for D-VCd and VCd arms was 21.3 and 5.3 months, respectively. In the D-VCd arm, 149 patients (77.2%) received daratumumab monotherapy after completing 6 cycles of D-VCd; of those, 17 (11.4%) were still receiving treatment. The rates of deep hematological responses favored the D-VCd treatment arm (Table). At a median follow-up of 25.8 months, the rate of hematologic CR was significantly higher in the D-VCd arm vs the VCd arm (59.5% vs 19.2%; odds ratio [95% confidence interval (CI)], 6.03 [3.80-9.58]; P<0.0001). Similarly, more patients achieved a very good partial response or better (≥VGPR) (D-VCd vs VCd, 79.0% vs 50.3%; odds ratio [95% CI], 3.74 [2.39-5.86]; P<0.0001). Among patients who responded, the median time from randomization to ≥VGPR was shorter in the D-VCd arm (0.56 months) vs the VCd arm (0.82 months). Comparable to the cardiac response analysis at 6 months (D-VCd vs VCd, 42% vs 22%), greater cardiac response rates were achieved with D-VCd compared with VCd at 18 months (53% vs 24%). Similarly, renal response rates remained superior with D-VCd vs VCd alone at 18 months (58% vs 26% compared with 6 months [54% vs 27%]). A total of 79 deaths occurred (D-VCd, N=34; VCd, N=45). In the D-VCd arm, only 1 additional grade 3/4 treatment-emergent adverse event occurred over 18 months vs 12 months (119 [61.7%] vs 118 [61.1%] patients) and no additional infusion-related reactions were reported. OS will be analyzed and major organ deterioration PFS will be updated after approximately 200 events have occurred. Conclusions: These results demonstrate the sustained clinical benefits of D-VCd vs VCd in terms of hematologic and organ responses with longer follow-up, although it should be noted that many patients in the D-VCd arm received daratumumab monotherapy following 6 cycles of D-VCd, while patients in the VCd group stopped study treatment. Nevertheless, the study continues to support the use of D-VCd over VCd alone in patients with newly diagnosed AL amyloidosis. Following its recent approval, D-VCd represents a new SOC for patients with AL amyloidosis. Figure 1 Figure 1. Disclosures Comenzo: Prothena Biosciences: Consultancy, Research Funding; Takeda: Research Funding; Unum: Membership on an entity's Board of Directors or advisory committees, Research Funding; Karyopharm: Research Funding; Caelum: Consultancy, Research Funding; Sanofi-Aventis: Membership on an entity's Board of Directors or advisory committees; Janssen: Patents & Royalties: WO2016187546A1, Research Funding. Palladini: Pfizer: Honoraria; Siemens: Honoraria; Janssen Global Services: Honoraria, Other: advisory board fees. Kastritis: Pfizer: Consultancy, Honoraria, Research Funding; Takeda: Honoraria; Amgen: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Genesis Pharma: Honoraria. Minnema: Janssen: Consultancy; BMS: Consultancy; Kite/Gilead: Consultancy; Celgene: Other: Travel expenses; Alnylam: Consultancy; Cilag: Consultancy. Wechalekar: Amgen: Research Funding; Janssen: Consultancy; Takeda: Honoraria; Celgene: Honoraria; Caelum Biosciences: Other: Clinical Trial Funding; Alexion, AstraZeneca Rare Disease: Consultancy. Jaccard: Pfizer: Honoraria; Abbvie: Honoraria; Janssen: Membership on an entity's Board of Directors or advisory committees. Dispenzieri: Janssen: Consultancy, Research Funding; Sorrento Therapeutics: Consultancy; Oncopeptides: Consultancy; Alnylam: Research Funding; Pfizer: Research Funding; Takeda: Research Funding. Lee: Karyopharm: Consultancy; Celgene: Consultancy; Takeda Pharmaceuticals: Consultancy, Research Funding; Amgen: Consultancy, Research Funding; GlaxoSmithKline: Consultancy, Research Funding; Sanofi: Consultancy; Genentech: Consultancy; Legend Biotech: Consultancy; Janssen: Consultancy, Research Funding; Oncopetides: Consultancy; Bristol Myers Squibb: Consultancy; Regeneron: Research Funding. Sanchorawala: Oncopeptide: Research Funding; Karyopharm: Research Funding; Sorrento: Research Funding; Pfizer: Honoraria; Proclara: Membership on an entity's Board of Directors or advisory committees; Regeneron: Membership on an entity's Board of Directors or advisory committees; Caelum: Membership on an entity's Board of Directors or advisory committees, Research Funding; Abbvie: Membership on an entity's Board of Directors or advisory committees; Prothena: Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Research Funding; Celgene: Research Funding. Gibbs: AbbVie: Consultancy; Janssen, Celgene, Amgen, Takeda, BMS and Pfizer: Consultancy, Honoraria. Mollee: Janssen, Pfizer: Research Funding; Amgen, BMS, Janssen, Caelum, EUSA, Pfizer, SkylineDx, Takeda: Membership on an entity's Board of Directors or advisory committees, Other: No personal fees received. Venner: BMS: Honoraria; Amgen: Research Funding; Celgene: Research Funding; Amgen: Honoraria; Takeda: Honoraria; Janssen: Honoraria; Sanofi: Honoraria; Pfizer: Honoraria. Schönland: Janssen: Honoraria, Other: Travel grants, Research Funding; Pfizer: Honoraria; Takeda: Honoraria, Other: Travel grants; Prothena: Honoraria, Other: Travel grants; Sanofi: Research Funding. Suzuki: Abie: Honoraria; Sanofi: Honoraria; Novartis: Honoraria; ONO: Honoraria; Takeda: Consultancy, Honoraria; Amgen: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Research Funding; Bristol-Myers Squibb: Honoraria, Research Funding; Janssen: Consultancy, Honoraria. Kim: BMS: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding. Cibeira: Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Akcea: Honoraria, Membership on an entity's Board of Directors or advisory committees. Beksac: Oncopeptides: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Sanofi: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; BMS: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Takeda: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Amgen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Libby: Genentech: Research Funding; BMS: Research Funding; GSK: Research Funding; Janssen: Consultancy, Research Funding. Valent: Caelum Biosciences: Other: Clinical Trial Funding; Celgene Corporation: Speakers Bureau; Takeda Pharmaceuticals: Speakers Bureau; Amgen: Speakers Bureau. Hungria: Amgen, BMS, Celgene, Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Support for attending meetings/travel ; Abbvie: Honoraria; Sanofi: Honoraria, Other: Support for attending meetings/travel ; Takeda: Honoraria. Wong: Amgen: Consultancy; Genentech: Research Funding; Fortis: Research Funding; Janssen: Research Funding; GloxoSmithKlein: Research Funding; Dren Biosciences: Consultancy; Caelum: Research Funding; BMS: Research Funding; Sanofi: Membership on an entity's Board of Directors or advisory committees. Rosenzweig: Janssen: Consultancy, Speakers Bureau; Bristol Myers Squibb: Speakers Bureau; Akcea: Speakers Bureau; Takeda: Speakers Bureau; Onocopeptides: Speakers Bureau. Bumma: Amgen, Sanofi: Speakers Bureau; Janssen, Oncopeptides, Sanofi: Consultancy. Tran: Janssen: Current Employment, Current equity holder in publicly-traded company. Qin: Janssen: Current Employment. Khaled: Jazz: Honoraria; Astellas: Honoraria; Alexion: Honoraria, Speakers Bureau; Omeros: Honoraria; Janssen: Current Employment. Vermeulen: Janssen: Current Employment, Current equity holder in publicly-traded company.
NIMG-59. RADIOMICS-PREDICTED T CELL DYNAMICS STRATIFY SURVIVAL AFTER DENDRITIC CELL VACCINE THERAPY FOR PRIMARY GLIOBLASTOMA
Bond, K. Elizabeth, León, Gustavo De , Urcuyo, Javier , Singleton, Kyle , Clark-Swanson, Kamala , Sereduk, Christopher, Hu, Leland , Swanson, Kristin R. , Swanson, Kristin R , Hawkins‐Daarud, Andrea , Leon, Gustavo De, Curtin, Lee , Sereduk, Chris , Tran, Nhan L. , Parney, Ian F.

Mayo Clinic

Neuro-Oncology | November 18, 2021 | Volume: 23 | Issue: Supplement_6 | Pages: vi142-vi143

10.1093/neuonc/noab196.557 Get It

Abstract INTRODUCTION Dendritic cells (DCs) are potent antigen presenting cells that can be exploited to initiate an adaptive anti-tumoral immune response. DC vaccine clinical trials for primary glioblastoma (GBM) have reported prolonged progression-free survival without any impact on overall survival (OS). We report a radiomics approach that identifies a subpopulation of patients with prolonged OS in clinical trial MC1272. METHODS Twenty adults with primary GBM undergoing standard-of-care therapy were enrolled in MC1272. Autologous DCs were pulsed with allogenic GBM cell lines to generate vaccines that were administered for up to twelve cycles. Standard brain imaging was obtained at the initiation of treatment and two months afterwards. An independent cohort of image-localized biopsies underwent RNA sequencing followed by cellular deconvolution to estimate T cell abundance. A machine learning model was trained to predict intratumoral T cell abundance from imaging features, and the model was applied to MC1272 patient imaging. RESULTS Voxelwise predictions of T cell abundance were generated for each patient’s pre- and post-treatment images. The difference in total intratumoral T cell abundance between imaging timepoints classified patients into increasing or decreasing T cell groups. Patients whose T cells increased had longer OS (median, 21 months) than those whose T cells decreased (median, 10 months; p=0.0035). The significance remained in a Cox proportional hazards analysis that adjusted for patient age and sex (p=0.011). CONCLUSIONS A spatially-resolved radiomics model detected that an intratumoral T cell influx after DC vaccine therapy was associated with prolonged OS. The “post-treatment” imaging in this study was obtained a mere two months after DC vaccine initiation, suggesting that our radiomics model can provide an early indication of treatment responsiveness and prognosis in these patients.
NIMG-72. QUANTIFYING INTRA-TUMOR MULTI-GENE HETEROGENEITY OF GBM FROM MRI USING A DATA-INCLUSIVE MACHINE LEARNING ALGORITHM
Hu, Leland , Singleton, Kyle , Sereduk, Christopher, Swanson, Kristin R. , Li, Jing , Swanson, Kristin R , Wang, Lujia , Hawkins‐Daarud, Andrea , Sereduk, Chris , Tran, Nhan L.

Mayo Clinic

Neuro-Oncology | November 18, 2021 | Volume: 23 | Issue: Supplement_6 | Pages: vi145-vi146

10.1093/neuonc/noab196.569 Get It

Abstract Intra-tumor genetic heterogeneity is an important cause of treatment failure of GBM. Using MRI and image-localized biopsies, it is possible to train machine learning (ML) models to predict regional genetic status. However, biopsy samples are limited, making it difficult to train a robust ML model. We proposed a data-inclusive model called Weakly Supervised Ordinal Support Vector Machines (WSO-SVM) which leverages the vast amount of MRI data outside the sparsely sampled biopsy regions to augment the biopsy samples to improve ML accuracy. Our study included a unique dataset of 104 image-localized biopsies with spatially matched multiparametric MRI from 30 untreated Glioblastoma (GBM) patients. Each biopsy sample went through genetic sequencing analysis and our study focused on two GBM hallmark genes, EGFR and PDGFRA. For each gene, a biopsy sample was labeled as “altered” if the copy number of this gene was amplified or a mutation was found, and “non-altered” otherwise. From the localized region of six MRI contrasts from T1gd, T2w, diffusion and perfusion imaging, over 300 texture features were extracted. To account for biopsy sample location uncertainty, six neighboring regions of the biopsy sample including four neighbors two pixels away from the biopsy location and two neighbors on adjacent slices were also included in model training. WSO-SVM achieved 0.83 accuracy, 0.77 sensitivity, and 0.86 specificity for classifying EGFR; 0.77 accuracy, 0.74 sensitivity, and 0.79 specificity for classifying PDGFRA, based on 10-fold cross validation. Furthermore, using the trained models, we generated regional EGFR and PDGFRA alteration maps for each patient within the enhancing and non-enhancing tumoral areas. On average we found a greater proportion of enhancing tumor with co-alteration than non-enhancing tumor, while this trend was reversed when considering only one altered gene. The ratio of EGFR vs PDGFRA alterations was higher in non-enhancing tumor than enhancing tumor.
CSIG-08. ABT-414 RESISTANT GBM TUMORS HARBOR THE TEK S466I MUTATION AND EXHIBIT INCREASED STEMNESS
Blomquist, Mylan, Sereduk, Christopher, Rabichow, Benjamin E. , Miller, Aunay , Marin, Bianca M. , Lasorella, Anna , Marin, Bianca M , Noviello, Teresa , D’Angelo, Fulvio , Sereduk, Chris , White, Forest M. , Sarkaria, Jann N. , Iavarone, Antonio , Ceccarelli, Michele , Tran, Nhan L.

Mayo Clinic

Neuro-Oncology | November 18, 2021 | Volume: 23 | Issue: Supplement_6 | Pages: vi34-vi35

10.1093/neuonc/noab196.134 Get It

Abstract Glioblastoma (GBM), the most common primary brain tumor in adults, remains uniformly fatal due to the lack of effective targeted therapies for this aggressive malignancy. Genomic amplification of epidermal growth factor receptor (EGFR) occurs in 40-60% of primary GBM. Half of all EGFR-amplified cases of GBM also harbor EGFRvIII, a constitutively active, truncated variant of EGFR. The incidence of EGFR alterations in GBM makes inhibition of EGFR/EGFRvIII an attractive therapeutic approach. Depatuxizumab mafodotin (ABT-414) is an antibody-drug conjugate comprised of ABT-806, a mAB against EGFR, and a cytotoxic payload (monomethyl auristatin F). ABT-414 therapy initially showed promising results as an EGFRvIII therapy in vivo and in vitro; however, ABT414 failed to provide a survival benefit in phase I/II clinical trials, potentially due to therapeutic resistance. In this study, we seek to investigate the mechanisms of resistance to ABT-414 by performing whole exome, transcriptome and single cell RNA seq on ABT-414 resistant GBM PDX tumors. Our data showed an enrichment of mutations unique to the ABT-414 resistant tumors, including a point mutation (S466I) in TEK/TIE2 transmembrane angiopoietin receptor. In vitro expression of TEK S466I in GBM cells showed an increase in activation of ERK and STAT3 and increased TEK/TIE2 immunoprecipitation with EGFR compared to the wild-type TEK receptor. Furthermore, gene ontology analysis reveals that ABT-414-treated flank tumors exhibit increased activation of extracellular matrix organization and CNS developmental processes compared to flank tumors in the control treatment groups. ABT-414-treated tumors also demonstrate increased expression of inhibitor of differentiation (ID)1 and ID3, associated with stem-like phenotype in glioblastoma. Taken together, our data indicate that resistance to ABT-414 is mediated by both de novo mutations not detected in the parent tumor and adaptive dysregulation of pathways which may lead to dedifferentiation and therapeutic resistance.
PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and 68Ga‐PSMA‐11 PET Using Cyclotron‐Produced 68Ga
Thompson, Scott M. , Suman, Garima , Chen, Zongming E., Jondal, Danielle E. , Patra, Anurima , Ehman, Eric C. , Andrews, James C. , Fleming, Chad J. , Welch, Brian T. , Kurup, A. Nicholas , Roberts, Lewis R. , Watt, Kymberly D. , Truty, Mark J. , Smoot, Rory L. , Yin, Jun , Jacobson, Mark, Kemp, Bradley J. , Venkatesh, Sudhakar K. , Johnson, Geoffrey B. , Woodrum, David A. , Goenka, Ajit H. , Chen, Zong-ming E., Kurup, Anil N, Watt, K D , Cleary, Sean P. , Wang, Chen , Fogarty, Zachary C , Venkatesh, Sudhakar K , Roberts, Lewis R , Smoot, Rory L , Johnson, Geoffrey B , Kurup, Anil N , Thompson, Scott , Torbenson, Michael , Heimbach, Julie K. , Tran, Nguyen H. , Mahipal, Amit , Zemla, Tyler , Wang, Chen , Fogarty, Zachary C.

Mayo Clinic

Hepatology Communications | November 16, 2021 | Volume: 6 | Issue: 5 | Pages: 1172-1185

10.1002/hep4.1861 | PMID 34783177 Get It

Prostate‐specific membrane antigen (PSMA) is a validated target for molecular diagnostics and targeted radionuclide therapy. Our purpose was to evaluate PSMA expression in hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), and hepatic adenoma (HCA); investigate the genetic pathways in HCC associated with PSMA expression; and evaluate HCC detection rate with 68Ga‐PSMA‐11 positron emission tomography (PET). In phase 1, PSMA immunohistochemistry (IHC) on HCC (n = 148), CCA (n = 111), and HCA (n = 78) was scored. In a subset (n = 30), messenger RNA (mRNA) data from the Cancer Genome Atlas HCC RNA sequencing were correlated with PSMA expression. In phase 2, 68Ga‐PSMA‐11 PET was prospectively performed in patients with treatment‐naïve HCC on a digital PET scanner using cyclotron‐produced 68Ga. Uptake was graded qualitatively and semi‐quantitatively using standard metrics. On IHC, PSMA expression was significantly higher in HCC compared with CCA and HCA (P < 0.0001); 91% of HCCs (n = 134) expressed PSMA, which principally localized to tumor‐associated neovasculature. Higher tumor grade was associated with PSMA expression (P = 0.012) but there was no association with tumor size (P = 0.14), fibrosis (P = 0.35), cirrhosis (P = 0.74), hepatitis B virus (P = 0.31), or hepatitis C virus (P = 0.15). Overall survival tended to be longer in patients without versus with PSMA expression (median overall survival: 4.2 vs. 1.9 years; P = 0.273). FGF14 (fibroblast growth factor 14) mRNA expression correlated positively (rho = 0.70; P = 1.70 × 10‐5) and MAD1L1 (Mitotic spindle assembly checkpoint protein MAD1) correlated negatively with PSMA expression (rho = −0.753; P = 1.58 × 10‐6). Of the 190 patients who met the eligibility criteria, 31 patients with 39 HCC lesions completed PET; 64% (n = 25) lesions had pronounced 68Ga‐PSMA‐11 standardized uptake value: SUVmax (median [range] 9.2 [4.9‐28.4]), SUVmean 4.7 (2.4‐12.7), and tumor‐to‐liver background ratio 2 (1.1‐11). Conclusion: Ex vivo expression of PSMA in neovasculature of HCC translates to marked tumor avidity on 68Ga‐PSMA‐11 PET, which suggests that PSMA has the potential as a theranostic target in patients with HCC.